Compare Becton Dickinson and Co (BDX) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Huntington Bancshares Incorporated — how do they compare? Becton Dickinson and Co trades at $154.99 (market cap $41.51B), while Huntington Bancshares Incorporated trades at $18.1 (market cap $36.18B). The key difference: Becton Dickinson and Co and Huntington Bancshares Incorporated are close in size by market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| BDX | HBAN | |
|---|---|---|
Market Cap | $41.51B | $36.18B |
Sector | Health | Financials |
52-Week High | $185.39 | $19.27 |
52-Week Low | $135.49 | $15.02 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Huntington Bancshares (HBAN) trades at $17.93, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, and maintains a net income margin of 25.13%. Recent news highlights expansion in Texas and a fintech partnership award. Analyst consensus is a Buy with a $20.25 price target, suggesting potential upside.
HBAN presents a favorable outlook with earnings growth potential, supported by strategic acquisitions and solid fundamentals. Risks include integration challenges from recent M&A and competitive pressures in regional banking. The stock's current valuation below consensus target indicates room for appreciation, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
